Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases.
eosinophil-associated diseases
patient rights
public awareness
Journal
Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158
Informations de publication
Date de publication:
17 May 2023
17 May 2023
Historique:
medline:
17
5
2023
pubmed:
17
5
2023
entrez:
17
5
2023
Statut:
aheadofprint
Résumé
Eosinophil-associated diseases (EADs) are a group of conditions in which eosinophils (a type of white blood cell) are thought to play a key role in the disease and how it develops. Some EADs are common, such as atopic dermatitis (also called eczema) and a subtype of asthma called eosinophilic asthma, while others are rare, such as hypereosinophilic syndrome (a condition in which a person has a very high number of eosinophils in both the blood and one or more organs). People with EADs face many problems related to their conditions. Symptoms such as severe abdominal pain, itch, or shortness of breath impact both the patient as well as their friends and family. Patients with EADs also experience delays to diagnosis and treatment as well as financial barriers. Healthcare professionals sometimes fail to recognize the complex set of symptoms that characterize an EAD, and this may cause delays in reaching a correct diagnosis. As a result, it may take longer for a patient to get the best care and the most effective treatments, which may contribute to poor health. The goal of this charter is to describe the key elements of good quality care, which all people with EADs deserve, as well as to present an action plan to improve health and overall well-being for people with EADs.
Identifiants
pubmed: 37194573
doi: 10.2217/imt-2022-0312
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM